Lifitegrast sodium (SAR-1118) is an LFA-1 antagonist for the therapy of vascular complications of the eye. It inhibits T cell-mediated inflammation by blocking the binding of two cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus reducing overall inflammatory responses.

1119276-80-0

C29H24Cl2N2NaO7S

638.47

SAR1118-023;SAR-1118-023;SAR 1118-023;Xiidra;Lifitegrast sodium

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years